Aclaris Therapeutics, Inc.
ACRS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $192 | $73 | $1,027 | $825 |
| - Cash | $25 | $40 | $45 | $27 |
| + Debt | $3 | $4 | $2 | $3 |
| Enterprise Value | $170 | $37 | $984 | $800 |
| Revenue | $19 | $31 | $30 | $7 |
| % Growth | -40.1% | 5% | 340.1% | – |
| Gross Profit | $16 | $13 | $18 | $2 |
| % Margin | 85.1% | 42.1% | 59.8% | 30.3% |
| EBITDA | -$52 | -$115 | -$84 | -$64 |
| % Margin | -276.3% | -369.5% | -283.5% | -953.4% |
| Net Income | -$132 | -$88 | -$87 | -$91 |
| % Margin | -705.5% | -283.1% | -292.1% | -1,344% |
| EPS Diluted | -1.71 | -1.27 | -1.33 | -1.6 |
| % Growth | -34.6% | 4.5% | 16.9% | – |
| Operating Cash Flow | -$20 | -$78 | -$68 | -$52 |
| Capital Expenditures | -$0 | -$1 | -$1 | -$0 |
| Free Cash Flow | -$20 | -$80 | -$68 | -$52 |